137 related articles for article (PubMed ID: 30819619)
1. Discovery of (S)-6-methoxy-chroman-3-carboxylic acid (4-pyridin-4-yl-phenyl)-amide as potent and isoform selective ROCK2 inhibitors.
Pan J; Yin Y; Zhao L; Feng Y
Bioorg Med Chem; 2019 Apr; 27(7):1382-1390. PubMed ID: 30819619
[TBL] [Abstract][Full Text] [Related]
2. Discovery and optimization of triazine derivatives as ROCK1 inhibitors: molecular docking, molecular dynamics simulations and free energy calculations.
Shen M; Zhou S; Li Y; Pan P; Zhang L; Hou T
Mol Biosyst; 2013 Mar; 9(3):361-74. PubMed ID: 23340525
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a phenylpyrazole amide ROCK inhibitor as a tool molecule for in vivo studies.
Hu Z; Wang C; Glunz PW; Li J; Cheadle NL; Chen AY; Chen XQ; Myers JE; Guarino VR; Rose A; Sack JS; Sitkoff D; Taylor DS; Xu S; Yan C; Zhang H; Zhang L; Hennan J; Adam LP; Wexler RR; Quan ML
Bioorg Med Chem Lett; 2020 Nov; 30(21):127495. PubMed ID: 32798651
[TBL] [Abstract][Full Text] [Related]
4. Chroman-3-amides as potent Rho kinase inhibitors.
Chen YT; Bannister TD; Weiser A; Griffin E; Lin L; Ruiz C; Cameron MD; Schürer S; Duckett D; Schröter T; LoGrasso P; Feng Y
Bioorg Med Chem Lett; 2008 Dec; 18(24):6406-9. PubMed ID: 18990570
[TBL] [Abstract][Full Text] [Related]
5. Identification of 5H-chromeno[3,4-c]pyridine and 6H-isochromeno[3,4-c]pyridine derivatives as potent and selective dual ROCK inhibitors.
Hu Z; Wang C; Sitkoff D; Cheadle NL; Xu S; Muckelbauer JK; Adam LP; Wexler RR; Quan ML
Bioorg Med Chem Lett; 2020 Nov; 30(21):127474. PubMed ID: 32805407
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of urea-based ROCK2 inhibitors.
Wang L; Qi J; Fan M; Yao L
Chem Biol Drug Des; 2021 Dec; 98(6):969-978. PubMed ID: 34581498
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.
Green J; Cao J; Bandarage UK; Gao H; Court J; Marhefka C; Jacobs M; Taslimi P; Newsome D; Nakayama T; Shah S; Rodems S
J Med Chem; 2015 Jun; 58(12):5028-37. PubMed ID: 26039570
[TBL] [Abstract][Full Text] [Related]
8. Discovery of potent and selective urea-based ROCK inhibitors: Exploring the inhibitor's potency and ROCK2/PKA selectivity by 3D-QSAR, molecular docking and molecular dynamics simulations.
Mei D; Yin Y; Wu F; Cui J; Zhou H; Sun G; Jiang Y; Feng Y
Bioorg Med Chem; 2015 May; 23(10):2505-17. PubMed ID: 25882521
[TBL] [Abstract][Full Text] [Related]
9. The selectivity and promiscuity of brain-neuroregenerative inhibitors between ROCK1 and ROCK2 isoforms: An integration of SB-QSSR modelling, QM/MM analysis and in vitro kinase assay.
Zhu L; Yang Y; Lu X
SAR QSAR Environ Res; 2016; 27(1):47-65. PubMed ID: 26854727
[TBL] [Abstract][Full Text] [Related]
10. ROCK inhibitors 4: Structure-activity relationship studies of 7-azaindole-based rho kinase (ROCK) inhibitors.
Bandarage UK; Court J; Gao H; Nanthakumar S; Come JH; Giroux S; Green J
Bioorg Med Chem Lett; 2021 Feb; 33():127721. PubMed ID: 33259926
[TBL] [Abstract][Full Text] [Related]
11. Phthalazinone-based lactams and cyclic ureas as ROCK2 selective inhibitors.
Hu Z; Sitkoff D; Glunz PW; Zou Y; Wang C; Muckelbauer JK; Adam LP; Wexler RR; Quan ML
Bioorg Med Chem Lett; 2023 May; 88():129304. PubMed ID: 37119973
[TBL] [Abstract][Full Text] [Related]
12. Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design.
Hobson AD; Judge RA; Aguirre AL; Brown BS; Cui Y; Ding P; Dominguez E; DiGiammarino E; Egan DA; Freiberg GM; Gopalakrishnan SM; Harris CM; Honore MP; Kage KL; Kapecki NJ; Ling C; Ma J; Mack H; Mamo M; Maurus S; McRae B; Moore NS; Mueller BK; Mueller R; Namovic MT; Patel K; Pratt SD; Putman CB; Queeney KL; Sarris KK; Schaffter LM; Stoll V; Vasudevan A; Wang L; Wang L; Wirthl W; Yach K
J Med Chem; 2018 Dec; 61(24):11074-11100. PubMed ID: 30384606
[TBL] [Abstract][Full Text] [Related]
13. Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3Kβ inhibitors.
Certal V; Halley F; Virone-Oddos A; Filoche-Rommé B; Carry JC; Gruss-Leleu F; Bertin L; Guizani H; Pilorge F; Richepin P; Karlsson A; Charrier V; Abecassis PY; Vincent L; Nicolas JP; Lengauer C; Garcia-Echeverria C; Schio L
Bioorg Med Chem Lett; 2014 Mar; 24(6):1506-10. PubMed ID: 24560540
[TBL] [Abstract][Full Text] [Related]
14. Discovery of bis-aryl urea derivatives as potent and selective Limk inhibitors: Exploring Limk1 activity and Limk1/ROCK2 selectivity through a combined computational study.
Cui J; Ding M; Deng W; Yin Y; Wang Z; Zhou H; Sun G; Jiang Y; Feng Y
Bioorg Med Chem; 2015 Dec; 23(23):7464-77. PubMed ID: 26545798
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Rho-kinase inhibitors by docking-based virtual screening.
Shen M; Yu H; Li Y; Li P; Pan P; Zhou S; Zhang L; Li S; Lee SM; Hou T
Mol Biosyst; 2013 Jun; 9(6):1511-21. PubMed ID: 23549429
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and evaluation of 3-quinoline carboxylic acids as new inhibitors of protein kinase CK2.
Syniugin AR; Ostrynska OV; Chekanov MO; Volynets GP; Starosyla SA; Bdzhola VG; Yarmoluk SM
J Enzyme Inhib Med Chem; 2016; 31(sup4):160-169. PubMed ID: 27590574
[TBL] [Abstract][Full Text] [Related]
17. Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension.
Shaw D; Hollingworth G; Soldermann N; Sprague E; Schuler W; Vangrevelinghe E; Duggan N; Thomas M; Kosaka T; Waters N; van Eis MJ
Bioorg Med Chem Lett; 2014 Oct; 24(20):4812-7. PubMed ID: 25248678
[TBL] [Abstract][Full Text] [Related]
18. 2,3,5-Trisubstituted pyridines as selective AKT inhibitors-Part I: Substitution at 2-position of the core pyridine for ROCK1 selectivity.
Lin H; Yamashita DS; Zeng J; Xie R; Wang W; Nidarmarthy S; Luengo JI; Rhodes N; Knick VB; Choudhry AE; Lai Z; Minthorn EA; Strum SL; Wood ER; Elkins PA; Concha NO; Heerding DA
Bioorg Med Chem Lett; 2010 Jan; 20(2):673-8. PubMed ID: 20006497
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological characterization of selective LIMK inhibitors.
Boland S; Bourin A; Alen J; Geraets J; Schroeders P; Castermans K; Kindt N; Boumans N; Panitti L; Vanormelingen J; Fransen S; Van de Velde S; Defert O
Bioorg Med Chem Lett; 2015 Sep; 25(18):4005-10. PubMed ID: 26233434
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a novel ROCK2 inhibitor with anti-migration effects via docking and high-content drug screening.
Chong CM; Kou MT; Pan P; Zhou H; Ai N; Li C; Zhong HJ; Leung CH; Hou T; Lee SM
Mol Biosyst; 2016 Aug; 12(9):2713-21. PubMed ID: 27354305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
